Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (247) Warfarin Sodium tablets, Barr Laboratories,
...Newly Approved Drug Therapies (247) Warfarin Sodium tablets, Barr Laboratories, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Warfarin Sodium tablets Company: Barr Laboratories Approval Status: Approved March 1997 Treatment Area: Anticoagulant, or "blood ...
View Page

2.  Study Posting (4519) Trial #106007, Atrial Fibrillation, Sydney, Australia
...Study Posting (4519) Trial #106007, Atrial Fibrillation, Sydney, Australia Trial Information The Warfarin-SMART Study Status: No longer recruiting Protocol Number: X03-0023 Sponsor: Company Division: Diagnostic Official Scientific Title: The Warfarin-SMART study Brief Summary: This study will evaluate the impact of patient self-management of ...
View Page

3.  Study Posting (3716) Trial #136152, Atrial Fibrillation, Waterbury, CT
...Study Posting (3716) Trial #136152, Atrial Fibrillation, Waterbury, CT Trial Information A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of Apixaban In ...
...the duration. Fingerstick INRs at all visits where doctors will be asked to adjust patients Warfarin or Warfarin placebo during their visits. Patient Inclusion Criteria: • 18 years or older • Permanent or ...
View Page

4.  Study Posting (1570) Trial #156483, Atrial Fibrillation, Morristown, NJ
...Fibrillation, Morristown, NJ Trial Information Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-Dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF) The ...
...prevent clots in brain and in the other organs than the standard of care with warfarin an oral anticoagulant whose doses are adjusted according to a regular monitoring of a blood ...
View Page

5.  Study Posting (1918) Trial #161373, Strokes, Savannah, GA
...to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) This study is to demonstrate the safety and efficacy ...
...will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months. Inclusion Criteria: • 21 years of age ...
View Page

6.  Study Posting (1918) Trial #160143, Strokes, Savannah, GA
...to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) This study is to demonstrate the safety and efficacy ...
...will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months. Patient Inclusion Criteria: • 21 years of ...
View Page

7.  Study Posting (1918) Trial #161375, Vascular Diseases, Savannah, GA
...to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) This study is to demonstrate the safety and efficacy ...
...will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months. Inclusion Criteria: • 21 years of age ...
View Page

8.  Study Posting (1918) Trial #161374, Atrial Fibrillation, Savannah, GA
...to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) This study is to demonstrate the safety and efficacy ...
...will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months. Inclusion Criteria: • 21 years of age ...
View Page

9.  Study Posting (1918) Trial #160144, Atrial Fibrillation, Savannah, GA
...to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) This study is to demonstrate the safety and efficacy ...
...will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin. The expected duration of the study is 24 months. Patient Inclusion Criteria: • 21 years of ...
View Page

10. Clinical Trial Results by Drug Names
...Clinical Trial Results by Drug Names Clinical Trial Result Information Title of Study: The Warfarin-SMART Study. Fast Facts: Protocol number: X03-0023 Sponsor: Roche Diagnostics Australia Pty Ltd Company ...
View Page

11.  Study Posting (2128) Trial #111288, Heart Disease, Ventura, CA
...to determine if the study drug (an investigational blood-thinning medication) is as good as warfarin (Coumadin®) in reducing the formation of blood clots in the hearts of patients with atrial ...
...blood clotting. All participants in the study will receive blood-thinning medication; half will take warfarin (Coumadin®), while the other half will take the investigational medication. Neither the study team nor ...
View Page

12.  Study Posting (5349) Trial #158413, Atrial Fibrillation, Orange, CA
...the Efficacy and Safety of Once- Weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) with Oral Adjusted-Dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients with Atrial Fibrillation The ...
...weekly subcutaneous injection of idrabiotaparinux is at least as effective as oral INR adjusted-dose warfarin in the prevention of stroke or systemic embolic event in patients with atrial fibrillation. Patient ...
View Page

13. Clinical Trial Results: Atrial Fibrillation
...Trial Results: Atrial Fibrillation Product Name: CoaguChek S Date of Report: To be Published The Warfarin-SMART Study. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed ...
View Page

14. Advanced/Specific Search Results CoaguChek S
...Trial Results: CoaguChek S Product Name: CoaguChek S Date of Report: To be Published The Warfarin-SMART Study. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information LLC. Designed ...
View Page

15.  Study Posting (1955) Trial #144716, Atrial Fibrillation, Haverhill, MA
...Fibrillation Age 21 or older with a history of A-Fib.  The need to take warfarin or coumidin on a daily basis.  Terry Stubbs MA, CCRC, CEO and President ActivMed Practices ...
View Page

16.  Study Posting (5193) Trial #155652, Atrial Fibrillation, Houston, TX
...TX The primary objective of this study is to determine if apixaban is noninferior to warfarin in the endpoint of stroke and systemic embolism in individuals with AF Patient Inclusion Criteria ...
View Page

17.  Study Posting (4561) Trial #113411, Atrial Fibrillation, Oviedo, FL
...for Adult Subjects with Nonvalvular Atrial Fibrillation Protocol Title: Protocol CV185030: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in ...
View Page

18.  Study Posting (1955) Trial #162807, Atrial Fibrillation, Haverhill, MA
...are age 21 years or older and have been diagnosed with A-FIB and take Warfarin or Coumadin you may qualify for this study. JoEllen or Pam, research coordinators ActivMed Practices ...
View Page

19.  CenterWatch: New Medical Therapies in Disease Category (233), Thrombocytopenia and Thrombocytopenia Prevention
...The subjects received 150 mg dabigatran etexilate orally, twice daily or an approved regimen of warfarin for six months. The primary composite endpoint was incidence of recurrent symptomatic VTE and deaths ...
...etexilate met the primary outcome of the trial and was non-inferior to dose-adjusted warfarin (2.4% versus 2.1%). In addition, dabigatran etexilate demonstrated a significant 37% reduction in ...
View Page

20.  Study Posting (1360) Trial #134875, Atrial Fibrillation, Lexington, KY
...conducting a research study to demonstrate the effi cacy of a study drug compared to Warfarin (Coumadin) for the prevention of strokes in patients with non-valvular atrial fibrillation. You may ...
...your willingness to take part in this study may result in the possibility of discontinuing Warfarin (Coumadin) therapy. For further information, please contact the study coordinator, at (859) 323-8663. University ...
View Page